Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors “A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome”

Cancer Immunology, Immunotherapy

Volumn 65, Issue 6, 2016, Pages 769-770

  Spain, Lavinia ^a   Larkin, James ^a   Martin Liberal, Juan ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; INSULIN DERIVATIVE; MONOCLONAL ANTIBODY;

COLITIS; DISEASE ASSOCIATION; DISEASE COURSE; GENOTYPE; HLA TYPING; HUMAN; IMMUNOTOXICITY; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; DIABETES MELLITUS;

ANTIBODIES, MONOCLONAL; DIABETES MELLITUS; HUMANS; INSULINS;

EID: 84969786976     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1845-2     Document Type: Letter

References (4)

1. Hansen E, Sahasrabudhe D, Sievert L (2016) A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother. doi:10.1007/s00262-016-1835-4
2. Martin-Liberal J, Furness AJ, Joshi K et al (2015) Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 64:765–767
3. International MHC and Autoimmunity Genetics Network, Rioux JD et al (2009) Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci USA 106:18680–18685
4. Dubin K, Callahan MK, Ren B et al (2016) Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 7:10391